CARB-X to fund development of drug to rejuvenate ineffective antibiotics
CARB-X announced today that it is awarding up to $2.2 million to the University of Queensland s Institute for Molecular Bioscience (IMB) to continue developing new compounds designed to boost antibiotics that have become ineffective against drug-resistant bacterial infections.
The award will help fund IMB s octapeptins research program, which is developing octapeptin peptides that can disrupt the protective outer cell membrane of drug-resistant gram-negative bacteria, allowing antibiotics that have lost efficacy to work again. IMB researchers are currently trying to identify which antibiotics octapeptins are best at helping and can be combined with.